Amplimmune, Inc.

Amplimmune, Inc.

Amplimmune, Inc.

Date Founded



45 West Watkins Mill Road,Gaithersburg, MD 20878

Type of Company


Employees (Worldwide)

1,001 - 5,000


Hospitals & Patient Services
Medical Support Services

Company Description

Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD.

Contact Data
Trying to get in touch with decision makers at Amplimmune, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Senior Director-Clinical Operations




Board of Directors

Founder at NextCure, Inc.

Director at ProteinSimple, Inc.

Paths to Amplimmune, Inc.
Potential Connections via
Relationship Science
Amplimmune, Inc.
Recent Transactions
Details Hidden

AstraZeneca Plc, MedImmune LLC purchase Amplimmune, Inc. from InterWest Partners, LLC

Transaction Advisors
Legal Advisor

Advised onMedImmune LLC, AstraZeneca Plc purchase Amplimmune, Inc. from InterWest Partners, LLC

Non-Profit Donations & Grants
Details Hidden

The Wellcome Trust Ltd. provides welfare and charitable services. It supports the discovery of vaccines and drug-resistant infections, diversity and inclusion, open research, government investment in research, data sharing in public health emergencies, and strengthening ecosystems. The company was founded in 1936 and is headquartered in London, UK.

Details Hidden

InterWest Partners focuses on early-stage investments in life sciences and information technology companies. Within the life sciences sector, the firm invests in a range of early-stage opportunities including the funding of preclinical companies with great potential. They also consider investing in or starting new companies around clinical or commercial stage assets. Within the information technology sector, InterWest looks for early-stage companies with near-term ROI-based value propositions. They favor investments in development-stage companies. Investments average $10 million to $15 million over the life of a company. InterWest serves as the lead investor in the majority of their investments.

Details Hidden

Associate Director at Johns Hopkins University - Bloomberg-Kimmel Institute for Cancer Immunotherapy at Sidney Kimmel Comprehensive Cancer Center

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Amplimmune, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Amplimmune, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Amplimmune, Inc..